Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying alpha-Synuclein-Containing Extracellular Vesicles

Objective To develop a reliable and fast assay to quantify the alpha-synuclein (alpha-syn)-containing extracellular vesicles (EVs) in CSF and to assess their diagnostic potential for Parkinson disease (PD). Methods A cross-sectional, multicenter study was designed, including 170 patients with PD and 131 healthy controls (HCs) with a similar distribution of age and sex recruited from existing center studies at the University of Washington and Oregon Health and Science University. CSF EVs carrying alpha-syn or aggregated alpha-syn were quantified using antibodies against total or aggregated alpha-syn, respectively, and highly specific, sensitive, and rapid assays based on the novel Apogee nanoscale flow cytometry technology. Results No significant differences in the number and size distribution of total EVs between patients with PD and HCs in CSF were observed. When examining the total alpha-syn-positive and aggregated alpha-syn-positive EV subpopulations, the proportions of both among all detected CSF EVs were significantly lower in patients with PD compared to HCs (p < 0.0001). While each EV subpopulation showed better diagnostic sensitivity and specificity than total CSF alpha-syn measured directly with an immunoassay, a combination of the 2 EV subpopulations demonstrated a diagnostic accuracy that attained clinical relevance (area under curve 0.819, sensitivity 80%, specificity 71%). Conclusion Using newly established, sensitive nanoscale flow cytometry assays, we have demonstrated that total alpha-syn-positive and aggregated alpha-syn-positive EVs in CSF may serve as a helpful tool in PD diagnosis. Classification of Evidence This study provides Class III evidence that total and aggregated alpha-syn-positive EVs in CSF identify patients with PD.